Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Stock Information for Tempest Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.